Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

NMRA

Neumora Therapeutics Inc.

Sep 06 • 04:00PM ET

10.46

Dollar change -0.33
Percentage change -3.06	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM IWO VTWO VXF SBIO VTWG SCHA ONEQ RSSL

Index	RUT	P/E	-	EPS (ttm)	-1.74	Insider Own	65.70%	Shs Outstand	158.83M	Perf Week	-6.69%
Market Cap	1.67B	Forward P/E	-	EPS next Y	-1.60	Insider Trans	-0.10%	Shs Float	54.90M	Perf Month	-11.28%
Income	-274.18M	PEG	-	EPS next Q	-0.40	Inst Own	27.62%	Short Float	17.49%	Perf Quarter	5.34%
Sales	0.00M	P/S	-	EPS this Y	58.92%	Inst Trans	-	Short Ratio	12.21	Perf Half Y	-44.95%
Book/sh	2.38	P/B	4.39	EPS next Y	-7.13%	ROA	-71.73%	Short Interest	9.60M	Perf Year	-
Cash/sh	2.32	P/C	4.50	EPS next 5Y	-	ROE	-77.08%	52W Range	8.33 - 21.00	Perf YTD	-38.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-71.91%	52W High	-50.19%	Beta	3.58
Dividend TTM	-	Quick Ratio	17.22	Sales past 5Y	0.00%	Gross Margin	-	52W Low	25.57%	ATR (14)	0.64
Dividend Ex-Date	-	Current Ratio	17.22	EPS Y/Y TTM	-100.60%	Oper. Margin	0.00%	RSI (14)	38.60	Volatility	5.30% 5.54%
Employees	124	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	23.14
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-45.53%	Payout	-	Rel Volume	0.39	Prev Close	10.79
Sales Surprise	-	EPS Surprise	0.54%	Sales Q/Q	-	Earnings	Aug 06 BMO	Avg Volume	786.56K	Price	10.46
SMA20	-8.34%	SMA50	-7.77%	SMA200	-18.68%	Trades		Volume	302,832	Change	-3.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-24	Initiated	Needham	Buy	$23
Jul-08-24	Initiated	Mizuho	Outperform	$20
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

Aug-14-24 07:00AM	Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders (GlobeNewswire)
Aug-06-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-20-24 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
08:52AM	Loading…
May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Loading…
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
07:54PM	Loading…
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84% +6.73%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pinto Joshua	Chief Financial Officer	Aug 27 '24	Sale	11.39	15,693	178,806	138,965	Aug 27 05:58 PM
Pinto Joshua	Chief Financial Officer	Aug 26 '24	Sale	11.78	31,642	372,588	154,658	Aug 26 06:17 PM
Pinto Joshua	Chief Financial Officer	Aug 22 '24	Sale	11.63	28,496	331,468	210,469	Aug 26 06:17 PM
Pinto Joshua	Chief Financial Officer	Aug 23 '24	Sale	11.59	24,169	280,005	186,300	Aug 26 06:17 PM
Pinto Joshua	Officer	Aug 22 '24	Proposed Sale	11.90	100,000	1,190,000		Aug 22 09:48 AM
Burow Kristina	Director	Nov 13 '23	Buy	11.75	31,653	371,923	4,127,850	Nov 15 06:55 PM
Burow Kristina	Director	Nov 14 '23	Buy	11.98	3,357	40,217	4,131,207	Nov 15 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 13 '23	Buy	11.75	31,653	371,923	4,127,850	Nov 15 06:54 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 14 '23	Buy	11.98	3,357	40,217	4,131,207	Nov 15 06:54 PM
Burow Kristina	Director	Nov 08 '23	Buy	11.03	92,251	1,017,821	4,047,843	Nov 13 07:01 PM
Burow Kristina	Director	Nov 09 '23	Buy	10.53	31,079	327,262	4,078,922	Nov 13 07:01 PM
Burow Kristina	Director	Nov 10 '23	Buy	11.49	17,275	198,481	4,096,197	Nov 13 07:01 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 08 '23	Buy	11.03	92,251	1,017,821	4,047,843	Nov 13 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 09 '23	Buy	10.53	31,079	327,262	4,078,922	Nov 13 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 10 '23	Buy	11.49	17,275	198,481	4,096,197	Nov 13 07:00 PM
Burow Kristina	Director	Nov 06 '23	Buy	11.55	43,082	497,597	3,925,400	Nov 07 07:00 PM
Burow Kristina	Director	Nov 07 '23	Buy	11.50	30,192	347,208	3,955,592	Nov 07 07:00 PM
Burow Kristina	Director	Nov 03 '23	Buy	11.38	22,420	255,140	3,882,318	Nov 07 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 06 '23	Buy	11.55	43,082	497,597	3,925,400	Nov 07 06:59 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 07 '23	Buy	11.50	30,192	347,208	3,955,592	Nov 07 06:59 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 03 '23	Buy	11.38	22,420	255,140	3,882,318	Nov 07 06:59 PM
Burow Kristina	Director	Sep 28 '23	Buy	13.44	41,951	563,699	3,825,338	Sep 29 06:55 PM
Burow Kristina	Director	Sep 29 '23	Buy	13.98	34,560	483,149	3,859,898	Sep 29 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 28 '23	Buy	13.44	41,951	563,699	3,825,338	Sep 29 06:53 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 29 '23	Buy	13.98	34,560	483,149	3,859,898	Sep 29 06:53 PM
Burow Kristina	Director	Sep 26 '23	Buy	11.73	34,000	398,820	3,758,883	Sep 27 08:19 PM
Burow Kristina	Director	Sep 27 '23	Buy	12.31	24,504	301,644	3,783,387	Sep 27 08:19 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 26 '23	Buy	11.73	34,000	398,820	3,758,883	Sep 27 08:18 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 27 '23	Buy	12.31	24,504	301,644	3,783,387	Sep 27 08:18 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 25 '23	Buy	11.22	60,740	681,464	3,724,883	Sep 25 09:38 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 22 '23	Buy	11.14	40,000	445,600	3,664,143	Sep 25 09:38 PM
Burow Kristina	Director	Sep 25 '23	Buy	11.22	60,740	681,464	3,724,883	Sep 25 09:37 PM
Burow Kristina	Director	Sep 22 '23	Buy	11.14	40,000	445,600	3,664,143	Sep 25 09:37 PM
Burow Kristina	Director	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:23 AM
ARCH Venture Partners X, LLC	10% Owner	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:16 AM
ARCH Venture Partners X, LLC	10% Owner	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:15 AM
Gosebruch Henry O	President & CEO	Sep 19 '23	Buy	12.62	15,000	189,370	15,000	Sep 19 09:47 PM
AMGEN INC	10% Owner	Sep 19 '23	Buy	17.00	1,764,705	29,999,985	35,368,653	Sep 19 07:52 PM

Open in Screener

SLRN

Acelyrin Inc

Sep 06 • 04:00PM ET

4.24

Dollar change -0.33
Percentage change -7.22	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VB IWN VBK VXF IBB VTWO IWC SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.06	Insider Own	35.69%	Shs Outstand	97.87M	Perf Week	-11.85%
Market Cap	423.19M	Forward P/E	-	EPS next Y	-2.10	Insider Trans	-0.03%	Shs Float	64.18M	Perf Month	-14.17%
Income	-299.80M	PEG	-	EPS next Q	-0.80	Inst Own	70.20%	Short Float	10.80%	Perf Quarter	-0.24%
Sales	0.00M	P/S	-	EPS this Y	45.60%	Inst Trans	-	Short Ratio	6.32	Perf Half Y	-49.58%
Book/sh	5.71	P/B	0.74	EPS next Y	28.97%	ROA	-40.33%	Short Interest	6.93M	Perf Year	-84.23%
Cash/sh	6.36	P/C	0.67	EPS next 5Y	-	ROE	-43.79%	52W Range	3.36 - 28.24	Perf YTD	-43.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-52.66%	52W High	-84.99%	Beta	2.16
Dividend TTM	-	Quick Ratio	7.86	Sales past 5Y	0.00%	Gross Margin	-	52W Low	26.19%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	7.86	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	38.30	Volatility	7.46% 9.53%
Employees	130	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.86	Target Price	11.40
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-222.51%	Payout	-	Rel Volume	0.54	Prev Close	4.57
Sales Surprise	-	EPS Surprise	-10.26%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	1.10M	Price	4.24
SMA20	-8.70%	SMA50	-18.69%	SMA200	-30.55%	Trades		Volume	588,610	Change	-7.22%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-24	Downgrade	H.C. Wainwright	Buy → Neutral	$18 → $6
Jul-08-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$13
Dec-13-23	Initiated	Wells Fargo	Equal Weight	$11
Dec-08-23	Initiated	Citigroup	Neutral	$8
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Sep-05-23	Initiated	H.C. Wainwright	Buy	$44
May-30-23	Initiated	TD Cowen	Outperform
May-30-23	Initiated	Piper Sandler	Overweight	$68
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Jefferies	Buy	$31

Aug-22-24 07:00AM	ACELYRIN, INC. to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.42%
Aug-13-24 04:00PM	ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results (GlobeNewswire) -14.71%
03:37AM	Why Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now? (Insider Monkey)
Aug-06-24 04:30PM	ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 (GlobeNewswire)
Jun-05-24 07:00AM	ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 (GlobeNewswire)
07:00AM	Loading…
May-29-24 07:00AM	ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 (GlobeNewswire)
May-15-24 11:54AM	SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 08:01AM	ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Leadership Transition (GlobeNewswire)
Apr-29-24 04:05PM	ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 (GlobeNewswire)
Mar-28-24 10:53PM	SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-27-24 04:01PM	Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire)
Mar-21-24 11:12AM	ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study (Zacks) -6.49%
Mar-20-24 07:00AM	ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease (GlobeNewswire)
12:39AM	Loading…
12:39AM	Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen (FierceBiotech.com)
Mar-11-24 10:04AM	After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory (FierceBiotech.com) +10.96%
08:02AM	ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients (GlobeNewswire)
Feb-15-24 04:05PM	ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications (GlobeNewswire) +10.89%
Jan-10-24 11:30AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire) -5.08%
Jan-04-24 09:56AM	Final Deadline Approaching for Acelyrin, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of January 16, 2024 Lead Plaintiff Deadline (GlobeNewswire)
Jan-01-24 09:35AM	Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Dec-27-23 10:45AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Dec-20-23 04:30PM	ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors (GlobeNewswire) -5.94%
Dec-19-23 12:13AM	Robbins LLP Reminds Investors of Lawsuit Against Acelyrin, Inc. and Approaching Lead Plaintiff Deadline (GlobeNewswire)
Dec-18-23 04:14PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire) -7.49%
Dec-12-23 09:25PM	ACELYRIN, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2024 deadline (GlobeNewswire) +8.51%
Dec-11-23 09:35AM	SLRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire) -7.47%
Dec-04-23 03:00PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress - Hagens Berman (GlobeNewswire)
08:00AM	Loading…
08:00AM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
Nov-30-23 04:30PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire) +5.66%
Nov-28-23 05:55PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2023 deadline (GlobeNewswire) -32.41% +8.16%
01:44PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
Nov-27-23 09:09PM	Acelyrin blames CRO error for shocking phase 3 failure that sent shiver through biotech IPO market (FierceBiotech.com)
04:30PM	ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program (GlobeNewswire)
Nov-20-23 11:01AM	Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Nov-16-23 06:42PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
04:11PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Nov-07-23 05:11PM	Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing (GuruFocus.com) -8.70%
04:05PM	ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-23 07:00AM	ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer (GlobeNewswire)
Oct-31-23 04:30PM	ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023 (GlobeNewswire) -10.36%
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-03-23 07:00AM	ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development (GlobeNewswire)
Sep-15-23 05:39PM	Why Acelyrin Stock Plummeted 59% This Week (Motley Fool)
Sep-11-23 04:05PM	ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire) -54.12%
Sep-06-23 07:00AM	ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-23 07:22PM	Billionaire Ken Griffin Pours Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks) +7.70%
Aug-14-23 04:05PM	ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-07-23 04:30PM	ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023 (GlobeNewswire)
Jul-18-23 07:00AM	ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer (GlobeNewswire)
Jun-15-23 04:05PM	ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-09-23 04:10PM	ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
May-05-23 07:08PM	Drug Developer Acelyrin Raises $540 Million in IPO (The Wall Street Journal)

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Becker Daniel J.	Director	Jul 17 '24	Sale	6.86	1	7	2,999	Jul 19 06:18 PM
Lin Shao-Lee	Chief Executive Officer	Apr 01 '24	Sale	6.63	9,961	66,024	1,577,374	Apr 03 06:18 PM
Lin Shao-Lee	Chief Executive Officer	Feb 20 '24	Sale	7.60	15,701	119,403	1,587,335	Feb 22 07:04 PM
Lin Shao-Lee	Chief Executive Officer	Jan 02 '24	Sale	7.41	10,691	79,188	1,603,036	Jan 04 06:09 PM

NMRA

Neumora Therapeutics Inc.

SLRN

Acelyrin Inc

Upgrade your FINVIZ experience